Evidence map›Paper›PMID 41537395›Full record

ArticleACS synthetic biology2026

Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control.

Tahere Mokhtari, Mohammad N Taheri, Sarah Akhlaghi, Armin Aryannejad, Yuda Xiang, Vineet Mahajan, Kamyar Keshavarz, Amirreza Kiani, Samantha Yang, Samuel LoPresti and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tahere MokhtariDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.ORCID 0009-0009-9015-8314
Mohammad N TaheriDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Sarah AkhlaghiDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Armin AryannejadDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Yuda XiangDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.ORCID 0009-0004-9121-4019
Vineet MahajanDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Kamyar KeshavarzDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Amirreza KianiDepartment of Electrical and Computer Engineering, University of Toronto, Toronto, Ontario M5S 3G4, Canada.
Samantha YangDepartment of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.
Samuel LoPrestiDepartment of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.
Ryan LeGrawDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.
Kathryn A WhiteheadDepartment of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0002-0100-7824
Samira KianiDivision of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States.ORCID 0000-0003-2695-1501

Funding

Fate, Function and Genetic Engineering of Breast Milk Cells for Infant TherapyDP2HD098860 · NICHD · CARNEGIE-MELLON UNIVERSITY · PI WHITEHEAD, KATHRYN A. · 2018 to 2021
$2.4M
CRISPR logic circuits for safer and controllable gene therapiesR01EB024562 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIANI, SAMIRA · 2018 to 2021
$1.7M
NIBIB NIH HHS R01 EB024562NIBIB NIH HHS R01-EB024562NICHD NIH HHS DP2 HD098860NIH HHS DP2-HD098860
6 · The paper itself

Abstract

Temporal transcriptional modulation of immune-related genes offers powerful therapeutic potential for treating inflammatory diseases. Here we introduce an enhanced zinc finger (ZF)-based transcriptional repressor delivered via lipid nanoparticles for controlling immune signaling pathways

Indexed as

Anti-Inflammatory AgentsEpigenesis, GeneticNanoparticlesRNA, MessengerAnimalsHumansInflammationLipidsLiposomesMiceMice, Inbred C57BLMyeloid Differentiation Factor 88Zinc FingersAnti-Inflammatory AgentsLipid NanoparticlesLipidsLiposomesMyd88 protein, mouseMyeloid Differentiation Factor 88RNA, MessengerEpigenetic engineeringImmunomodulationInflammatory diseasesLipid nanoparticlesMyd88Zinc finger transcriptional repressors

Identifiers

PMID41537395
PMCPMC12930510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.